Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 154 articles:
HTML format
Text format



Single Articles


    November 2017
  1. ATALA A
    Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:985.
    PubMed     Text format    


  2. ATALA A
    Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    J Urol. 2017;198:984-985.
    PubMed     Text format    


  3. ATALA A
    Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer.
    J Urol. 2017;198:983-985.
    PubMed     Text format    


  4. CHANG SS
    Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2017;198:979-980.
    PubMed     Text format    


  5. CHANG SS
    Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:978-980.
    PubMed     Text format    


    October 2017
  6. WALLACE E, Higuchi R, Satya M, McCann L, et al
    Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  7. RYAN S, Serrell EC, Karabon P, Mills G, et al
    The Association Between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77715-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    September 2017
  8. CHANG SS
    Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation.
    J Urol. 2017;198:482-483.
    PubMed     Text format    


  9. CHANG SS
    Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    J Urol. 2017;198:482-483.
    PubMed     Text format    


  10. SANCHEZ A, Wszolek MF, Niemierko A, Clayman RH, et al
    Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77426-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    August 2017
  11. NARAYAN VM, Adejoro O, Schwartz I, Ziegelmann M, et al
    The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77411-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  12. SMITH ZL, Johnson SC, Golan S, McGinnis JR, et al
    Fistulous complications following radical cystectomy for bladder cancer: analysis of a large modern cohort.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77409-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  13. HURLE R, Lazzeri M, Vanni E, Lughezzani G, et al
    Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project.
    J Urol. 2017 Aug 25. pii: S0022-5347(17)77391-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    July 2017
  14. CHANG SS
    Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    J Urol. 2017;198:40.
    PubMed     Text format    


  15. CHANG SS
    Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    J Urol. 2017;198:39-41.
    PubMed     Text format    


    June 2017
  16. ARK JT, Alvarez JR, Koyama T, Bassett JC, et al
    Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race, and risk factors for bladder cancer.
    J Urol. 2017 Jun 24. pii: S0022-5347(17)76746-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  17. LAGUNA MP
    Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel.
    J Urol. 2017;197:1437-1438.
    PubMed     Text format    


    April 2017
  18. CHANG SS, Bochner BH, Chou R, Dreicer R, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
    J Urol. 2017 Apr 26. pii: S0022-5347(17)57836-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  19. RAVVAZ K, Walz ME, Weissert JA, Downs TM, et al
    Predicting non-muscle invasive bladder cancer recurrence and progression in a US population.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54785-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    March 2017
  20. KIM JH, Chung BI
    Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5alpha-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and
    J Urol. 2017 Mar 29. pii: S0022-5347(17)30226-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  21. BOEHM BE, Cornell JE, Wang H, Mukherjee N, et al
    Efficacy of Bacillus Calmette-guerin Strains for the Treatment of non-muscle Invasive Bladder Cancer: a Systematic Review and Network Meta-analysis.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39246-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  22. TOBERT CM, Hamilton-Reeves JM, Norian LA, Hung C, et al
    The Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications on Cystectomy for Bladder Cancer.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39247-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  23. CHANG SS
    Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer.
    J Urol. 2017;197.
    PubMed     Text format    


    February 2017
  24. STEINBERG GD
    Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis: R. Chou, S. Selph, D. I. Buckley, R. Fu, J. C. Griffin, S. Gr
    J Urol. 2017 Feb 6. pii: S0022-5347(16)32070-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


    January 2017
  25. CHANG SS
    Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;197:52-54.
    PubMed     Text format    


    December 2016
  26. BEUKERS W, van der Keur KA, Kandimalla R, Vergouwe Y, et al
    FGFR3, TERT and OTX1 as urinary biomarker combination for surveillance of bladder cancer patients in a large prospective multicenter study.
    J Urol. 2016 Dec 31. pii: S0022-5347(16)32099-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  27. SHENOY SP, Marla PK, Sharma P, Batchu CK, et al
    Re: Sequential bacillus Calmette-Guerin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes: C. Gan, S. Amery, K. Chatterton, M. S. Khan, K. Thomas and T
    J Urol. 2016 Dec 28. pii: S0022-5347(16)31927-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  28. CHOU R, Selph S, Buckley DI, Fu R, et al
    Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2016 Dec 24. pii: S0022-5347(16)32091-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


    October 2016
  29. CHOU R, Selph S, Buckley DI, Fu R, et al
    Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis.
    J Urol. 2016 Oct 22. pii: S0022-5347(16)31585-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  30. ATALA A
    Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness.
    J Urol. 2016;196:1314.
    PubMed     Text format    


  31. CHANG SS
    Re: Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor after Transurethral Resection for Bladder Cancer.
    J Urol. 2016;196:1045.
    PubMed     Text format    


  32. CHANG SS
    Re: Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: One-Year Results of a Multicentre Prospective Cohort Study.
    J Urol. 2016;196:1045-6.
    PubMed     Text format    


  33. CHANG SS
    Re: Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer: A Prospective, Blinded, International and Multicenter Validation Study.
    J Urol. 2016;196:1044-6.
    PubMed     Text format    


    August 2016
  34. SHIOTA M, Kiyoshima K, Yokomizo A, Takeuchi A, et al
    Suppressed recurrent bladder cancer after androgen suppression with androgen-deprivation therapy or 5alpha-reductase inhibitor.
    J Urol. 2016 Aug 6. pii: S0022-5347(16)30971-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  35. PENSON DF
    Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
    J Urol. 2016;196:352-4.
    PubMed     Text format    


  36. CHANG SS
    Re: Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival.
    J Urol. 2016;196:351-2.
    PubMed     Text format    


    July 2016
  37. BIRENDRA R, Kekre NS
    Re: A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer: J. C. Park, N. M. Gandhi, M. A. Carducci, M. A. Eisenberger, A. S. Baras, G. J. Netto, J. J. Li
    J Urol. 2016 Jul 6. pii: S0022-5347(16)30545-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


    June 2016
  38. CHANG SS, Boorjian SA, Chou R, Clark PE, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
    J Urol. 2016 Jun 15. pii: S0022-5347(16)30629-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  39. OZGUR BC, Yuceturk CN
    Re: Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer: M. L. Blute, Jr., T. J. Rushmer, F. Shi, B. J. Fuller, E. J. Abel, D. F. Jarrard and T. M. Downs J
    J Urol. 2016 Jun 10. pii: S0022-5347(16)30357-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  40. ZHANG S, Zhong G, He W, Yu H, et al
    LncRNA Up-regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of Recurrence.
    J Urol. 2016 Jun 4. pii: S0022-5347(16)30559-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  41. CHANG SS
    Re: Variation in Performance of Candidate Surgical Quality Measures for Muscle-Invasive Bladder Cancer by Hospital Type.
    J Urol. 2016;195:1721-2.
    PubMed     Text format    


  42. CHANG SS
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-Invasive Bladder Cancer: A Sign of Changing Tides.
    J Urol. 2016;195:1721.
    PubMed     Text format    


  43. CHANG SS
    Re: Cost-Effectiveness of Neoadjuvant Chemotherapy before Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Urol. 2016;195:1720-2.
    PubMed     Text format    


    May 2016
  44. MOSSANEN M, Macleod LC, Chu A, Wright JL, et al
    Comparative effectiveness of a patient centered pathology report for bladder cancer care.
    J Urol. 2016 May 19. pii: S0022-5347(16)30455-4. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  45. LARA J, Brunson A, Keegan TH, Malogolowkin M, et al
    Determinants of survival in adolescents and young adults with urothelial bladder cancer: results from the California Cancer Registry.
    J Urol. 2016 May 18. pii: S0022-5347(16)30454-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  46. GREGG JR, Emeruwa C, Wong J, Barocas DA, et al
    Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women.
    J Urol. 2016 May 6. pii: S0022-5347(16)30355-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  47. CHANG SS
    Re: Prognostic Factors and Risk Groups in T1G3 Non-Muscle-Invasive Bladder Cancer Patients Initially Treated with bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients.
    J Urol. 2016;195:1382.
    PubMed     Text format    


  48. CADEDDU JA
    Re: Recurrence Patterns after Open and Robot-Assisted Radical Cystectomy for Bladder Cancer.
    J Urol. 2016;195:1379-80.
    PubMed     Text format    


  49. WANG DS
    Re: Long-Term Changes in Renal Function Outcomes following Radical Cystectomy and Urinary Diversion.
    J Urol. 2016;195:1511.
    PubMed     Text format    


  50. MOREY AF
    Re: Outcomes of the Endoscopic Treatment of Bladder Neck Contractures in the Orthotopic Neobladder.
    J Urol. 2016;195:1508-9.
    PubMed     Text format    


  51. CHANG SS
    Re: Oncologic Outcomes following Robot-Assisted Radical Cystectomy with Minimum 5-Year Follow-up: The Roswell Park Cancer Institute Experience.
    J Urol. 2016;195:1381-2.
    PubMed     Text format    


  52. VENKATRAMANI V, Parekh DJ
    Editorial Comment.
    J Urol. 2016;195:1375.
    PubMed     Text format    


  53. KRISHNAN N, Liu X, Lavieri MS, Hu M, et al
    A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy.
    J Urol. 2016;195:1362-7.
    PubMed     Text format     Abstract available


  54. HUSSEIN AA, Hashmi Z, Dibaj S, Altartir T, et al
    Reoperations following Robot-Assisted Radical Cystectomy: A Decade of Experience.
    J Urol. 2016;195:1368-76.
    PubMed     Text format     Abstract available


    April 2016
  55. SEILER R, Lam LL, Erho N, Takhar M, et al
    Prediction of lymph node metastasis in bladder cancer patients using whole transcriptome gene expression signatures.
    J Urol. 2016 Apr 19. pii: S0022-5347(16)30204-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  56. CHANG SS
    Re: Endoscopic Molecular Imaging of Human Bladder Cancer Using a CD47 Antibody.
    J Urol. 2016;195.
    PubMed     Text format    


  57. ATALA A
    Re: Mutations in TERT Promoter and FGFR3 and Telomere Length in Bladder Cancer.
    J Urol. 2016;195.
    PubMed     Text format    


  58. GRIEBLING TL
    Re: Use of Preoperative Performance Status and Hemoglobin Concentration to Predict Overall Survival for Patients Aged >/=75 Years after Radical Cystectomy for Treatment of Bladder Cancer.
    J Urol. 2016;195.
    PubMed     Text format    


  59. GRIEBLING TL
    Re: Does Radical Cystectomy Outperform Other Bladder Preservative Treatments in Elderly Patients with Advanced Bladder Cancer?
    J Urol. 2016;195.
    PubMed     Text format    


  60. GRIEBLING TL
    Re: Different Patterns in the Prognostic Value of Age for Bladder Cancer-Specific Survival Depending on Tumor Stages.
    J Urol. 2016;195.
    PubMed     Text format    


  61. PATEL S, Cookson MS
    Radical Cystectomy-The Waiting is the Hardest Part...or is it?
    J Urol. 2016;195.
    PubMed     Text format    


    March 2016
  62. STEINBERG G
    Blue Light Cystoscopy Should Be Used Routinely for Bladder Cancer Detection.
    J Urol. 2016 Mar 16. pii: S0022-5347(16)03458-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  63. CASTLE EP
    Blue Light Cystoscopy Should Be Used Routinely for Bladder Cancer Detection.
    J Urol. 2016 Mar 16. pii: S0022-5347(16)03459-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  64. CHANG SS
    Re: Conditional Survival after Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time.
    J Urol. 2016;195:610-1.
    PubMed     Text format    


  65. CHANG SS
    Re: Factors Influencing the Length of Stay after Radical Cystectomy: Implications for Cancer Care and Perioperative Management.
    J Urol. 2016;195:610.
    PubMed     Text format    


    February 2016
  66. BHATTAR R, Priyadarshi S, Tomar V, Yadav SS, et al
    Re: Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer: M. L. Blute, Jr., T. J. Rushmer, F. Shi, B. J. Fuller, E. J. Abel, D. F. Jarrard and T. M. Downs J
    J Urol. 2016 Feb 11. pii: S0022-5347(16)00010-0. doi: 10.1016/j.juro.2015.
    PubMed     Text format    


  67. GAN C, Amery S, Chatterton K, Khan MS, et al
    Sequential BCG / Electromotive drug administration Mitomycin C (EMDA-MMC) as the standard intravesical regimen in high risk non muscle invasive bladder cancer (HR-NMIBC) - two year outcomes.
    J Urol. 2016 Feb 1. pii: S0022-5347(16)00226-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  68. SCHAEFFER EM
    Re: Multiparametric MRI Findings of Granulomatous Prostatitis after Intravesical bacillus Calmette-Guerin Therapy in a Patient Undergoing Active Surveillance.
    J Urol. 2016;195:371.
    PubMed     Text format    


  69. CHANG SS
    Re: Adjuvant Cisplatin-Based Combined Chemotherapy for Lymph Node (LN)-Positive Urothelial Carcinoma of the Bladder (UCB) after Radical Cystectomy (RC): A Retrospective International Study of >1500 Patients.
    J Urol. 2016;195:300.
    PubMed     Text format    


  70. CHANG SS
    Re: Multiparametric 3-T MRI for Differentiating Low- versus High-Grade and Category T1 versus T2 Bladder Urothelial Carcinoma.
    J Urol. 2016;195:299-300.
    PubMed     Text format    


  71. KATTAN MW
    Editorial Comment.
    J Urol. 2016;195:289.
    PubMed     Text format    


  72. BARTSCH G JR, Mitra AP, Mitra SA, Almal AA, et al
    Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.
    J Urol. 2016;195:493-8.
    PubMed     Text format     Abstract available


  73. OING C, Rink M, Oechsle K, Seidel C, et al
    Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
    J Urol. 2016;195:254-63.
    PubMed     Text format     Abstract available


  74. SONPAVDE G, Pond GR, Rosenberg JE, Bajorin DF, et al
    Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
    J Urol. 2016;195:277-82.
    PubMed     Text format     Abstract available


    January 2016
  75. LEITNER CV, Ederer IA, de Martino M, Hofbauer SL, et al
    Dynamic prognostication using conditional recurrence and progression estimates for patients with non-muscle invasive bladder cancer.
    J Urol. 2016 Jan 30. pii: S0022-5347(16)00225-1. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  76. MAMTANI R, Yang YX, Scott FI, Lewis JD, et al
    Association between itraconazole, a hedgehog-inhibitor, and bladder cancer.
    J Urol. 2016 Jan 23. pii: S0022-5347(16)00128-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  77. VON RUNDSTEDT FC, Kimal R, Ma J, Arnold J, et al
    Integrative pathway analysis of metabolic signature in bladder cancer - a linkage to the Cancer Genome Atlas Project and prediction of survival.
    J Urol. 2016 Jan 21. pii: S0022-5347(16)00072-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  78. SHARMA P, Henriksen CH, Zargar-Shoshtari K, Xin R, et al
    Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy.
    J Urol. 2016;195:47-52.
    PubMed     Text format     Abstract available


  79. NOGUERA-ORTEGA E, Rabanal RM, Secanella-Fandos S, Torrents E, et al
    gamma Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria.
    J Urol. 2016;195:198-205.
    PubMed     Text format     Abstract available


  80. LANGLE YV, Belgorosky D, Prack McCormick B, Sahores A, et al
    FGFR3 Down-Regulation is Involved in bacillus Calmette-Guerin Induced Bladder Tumor Growth Inhibition.
    J Urol. 2016;195:188-97.
    PubMed     Text format     Abstract available


  81. WANG DS
    Re: Intraoperative Continuous Norepinephrine Infusion Combined with Restrictive Deferred Hydration Significantly Reduces the Need for Blood Transfusion in Patients Undergoing Open Radical Cystectomy: Results of a Prospective Randomised Trial.
    J Urol. 2016;195:65.
    PubMed     Text format    


  82. WANG DS
    Re: Perioperative Complications and 90-Day Mortality of Radical Cystectomy in the Elderly (75+): A Retrospective, Multicentre Study.
    J Urol. 2016;195:65.
    PubMed     Text format    


  83. CHANG SS
    Re: Immediate versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial.
    J Urol. 2016;195:63-4.
    PubMed     Text format    


  84. HOMMA Y, Nakagawa T
    Optimal Dose and Duration of bacillus Calmette-Guerin Therapy for Urothelial Carcinoma of the Bladder.
    J Urol. 2016;195:9-10.
    PubMed     Text format    


  85. LERNER SP
    Editorial Comment.
    J Urol. 2016;195:59.
    PubMed     Text format    


    December 2015
  86. MATIN SF, Sfakianos JP, Espiritu PN, Coleman JA, et al
    Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates.
    J Urol. 2015;194:1567-74.
    PubMed     Text format     Abstract available


  87. WEIN AJ
    Re: The Microbiome of the Urinary Tract--A Role Beyond Infection.
    J Urol. 2015;194:1643-4.
    PubMed     Text format    


  88. WANG DS
    Re: Health-Related Quality of Life after Radical Cystectomy and Neobladder Reconstruction in Women: Impact of Voiding and Continence Status.
    J Urol. 2015;194:1585.
    PubMed     Text format    


  89. WANG DS
    Re: Impact of Surgeon Volume on the Morbidity and Costs of Radical Cystectomy in the USA: A Contemporary Population-Based Analysis.
    J Urol. 2015;194:1585-6.
    PubMed     Text format    


  90. LAGUNA MP
    Re: Risk Stratification for Bladder Recurrence of Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy.
    J Urol. 2015;194:1582-3.
    PubMed     Text format    


    November 2015
  91. PARK JC, Gandhi NM, Carducci MA, Eisenberger MA, et al
    A Retrospective Analysis of the Effect of Time from Diagnosis to Cystectomy on Survival in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy.
    J Urol. 2015 Nov 17. pii: S0022-5347(15)05238-6. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  92. JAMES AC, Izard JP, Holt SK, Calvert JK, et al
    Root-Causes and Modifiability of 30-day Hospital Readmissions Following Radical Cystectomy for Bladder Cancer Under 65 Years of Age.
    J Urol. 2015 Nov 7. pii: S0022-5347(15)05203-9. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  93. SEFTEL AD
    Re: Evaluating Sexual Function in Women after Radical Cystectomy as Treatment for Bladder Cancer.
    J Urol. 2015;194:1232.
    PubMed     Text format    


  94. PENSON DF
    Re: Lower Urinary Tract Symptoms and Risk of Bladder Cancer in Men: Results from the Health Professionals Follow-up Study.
    J Urol. 2015;194:1231-2.
    PubMed     Text format    


  95. CHANG SS
    Re: Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients.
    J Urol. 2015;194:1230.
    PubMed     Text format    


  96. KLATTE T, Seitz C, Rink M, Roupret M, et al
    ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    J Urol. 2015;194:1456-62.
    PubMed     Text format     Abstract available


  97. TAYLOR JA 3RD
    Editorial Comment.
    J Urol. 2015;194:1208.
    PubMed     Text format    


  98. XU W, Daneshmand S, Bazargani ST, Cai J, et al
    Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway.
    J Urol. 2015;194:1209-13.
    PubMed     Text format     Abstract available


    October 2015
  99. VAN OSCH FH, Jochems SH, van Schooten FJ, Bryan RT, et al
    Significant role for lifetime cigarette smoking in worsening bladder cancer and upper tract urothelial carcinoma prognosis: a meta-analysis.
    J Urol. 2015 Oct 30. pii: S0022-5347(15)05162-9. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  100. ZARGAR H, Zargar-Shoshtari K, Lotan Y, Shah JB, et al
    Final Pathologic Stage after Neoadjuvant Chemotherapy and Radical Cystectomy For Bladder Cancer: Does pT0 Predict Better Survival Than pTa/Tis/T1?
    J Urol. 2015 Oct 29. pii: S0022-5347(15)05153-8. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  101. LIN YC, Lin JF, Wen SI, Yang SC, et al
    Inhibition of High Basal Level of Autophagy Induces Apoptosis in Human Bladder Cancer Cells.
    J Urol. 2015 Oct 28. pii: S0022-5347(15)05148-4. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  102. LAMM DL
    Getting the Most Out of Bacillus Calmette-Guerin for Treatment of Bladder Cancer.
    J Urol. 2015 Oct 8. pii: S0022-5347(15)04960-5. doi: 10.1016/j.juro.2015.
    PubMed     Text format    


  103. ATALA A
    Re: Loss of Expression of the Tumour Suppressor Gene AIMP3 Predicts Survival following Radiotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2015;194:1162-3.
    PubMed     Text format    


  104. CHANG SS
    Re: MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer.
    J Urol. 2015;194:956.
    PubMed     Text format    


  105. CHANG SS
    Re: Potential Impact of 18F-FDG PET/CT on Patients Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    J Urol. 2015;194:955-6.
    PubMed     Text format    


  106. CHANG SS
    Re: Metastases in Normal-Sized Pelvic Lymph Nodes: Detection with Diffusion-Weighted MR Imaging.
    J Urol. 2015;194:954-5.
    PubMed     Text format    


    September 2015
  107. BROOKS M, Godoy G, Sun M, Shariat SF, et al
    External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival, and Overall Survival Following Radical Cystectomy.
    J Urol. 2015 Sep 4. pii: S0022-5347(15)04716-3. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  108. BANERJEE I, Yadav S, Priyadarshi S, Tomar V, et al
    Re: Clinical Outcomes of cT1 Micropapillary Bladder Cancer: D. L. Willis, M. I. Fernandez, R. J. Dickstein, S. Parikh, J. B. Shah, L. L. Pisters, C. C. Guo, S. Henderson, B. A. Czerniak, H. B. Grossman, C. P. Dinney and A. M. Kamat J Urol 2015;193:112
    J Urol. 2015 Sep 3. pii: S0022-5347(15)04139-7. doi: 10.1016/j.juro.2015.
    PubMed     Text format    


  109. PENSON DF
    Re: Association between Cannabis Use and the Risk of Bladder Cancer: Results from the California Men's Health Study.
    J Urol. 2015;194:667.
    PubMed     Text format    


  110. CHANG SS
    Re: Contemporary Cost-Effectiveness Analysis Comparing Sequential bacillus Calmette-Guerin and Electromotive Mitomycin versus bacillus Calmette-Guerin Alone for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2015;194:666.
    PubMed     Text format    


  111. GUPTA A, Long JB, Chen J, Gross CP, et al
    Risk of Vascular Toxicity with Platinum-based Chemotherapy in Elderly Patients with Bladder Cancer.
    J Urol. 2015 Sep 1. pii: S0022-5347(15)04708-4. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


    August 2015
  112. VAN KESSEL KE, Van Neste L, Lurkin I, Zwarthoff EC, et al
    Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Hematuria Patients.
    J Urol. 2015 Aug 28. pii: S0022-5347(15)04705-9. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  113. SATHE A, Koshy N, Schmid SC, Thalgott M, et al
    CDK4/6-inhibition controls proliferation of bladder cancer and transcription of RB1.
    J Urol. 2015 Aug 26. pii: S0022-5347(15)04685-6. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  114. YOKOMIZO A, Kanimoto Y, Okamura T, Ozono S, et al
    Randomized Controlled Study of the Efficacy, Safety and Quality of Life of Low-Dose Bacillus Calmette-Guerin Instillation Therapy for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2015 Aug 22. pii: S0022-5347(15)04674-1. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  115. CHANG SS
    Re: Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer.
    J Urol. 2015;194:334-5.
    PubMed     Text format    


  116. HAUTMANN RE
    Editorial Comment.
    J Urol. 2015;194:439.
    PubMed     Text format    


  117. FU LY, Adeniran AJ
    Adenocarcinoma Arising from a Bladder Diverticulum.
    J Urol. 2015;194:527-8.
    PubMed     Text format    


  118. WANG B, Wu S, Zeng H, Liu Z, et al
    CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    J Urol. 2015;194:556-62.
    PubMed     Text format     Abstract available


    July 2015
  119. SMITH ND, Prasad SM, Patel AR, Weiner AB, et al
    Bladder Cancer Mortality in the United States: A Geographic and Temporal Analysis of Socioeconomic and Environmental Factors.
    J Urol. 2015 Jul 30. pii: S0022-5347(15)04499-7. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  120. ZARGAR-SHOSHTARI K, Zargar H, Lotan Y, Shah JB, et al
    A Multi-Institutional Analysis of Outcomes in Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
    J Urol. 2015 Jul 20. pii: S0022-5347(15)04421-3. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  121. PIERZYNSKI JA, Hildebrandt MA, Kamat AM, Lin J, et al
    Genetic Variants within the Wnt/beta-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk.
    J Urol. 2015 Jul 11. pii: S0022-5347(15)04361-X. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  122. BLUTE ML JR, Rushmer TJ, Shi F, Fuller B, et al
    Renin-Angiotensin Inhibitors Decrease Recurrence After Turbt in Non-Muscle Invasive Bladder Cancer.
    J Urol. 2015 Jul 11. pii: S0022-5347(15)04360-8. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  123. CHANG SS
    Re: Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors.
    J Urol. 2015;194:261.
    PubMed     Text format    


  124. GEIJSEN ED, de Reijke TM, Koning CC, Zum Vorde Sive Vording PJ, et al
    Combining Mitomycin C and regional 70 MHz hyperthermia in patients with non-muscle invasive bladder cancer: a pilot study.
    J Urol. 2015 Jul 1. pii: S0022-5347(15)04307-4. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  125. CHANG SS
    Re: Intermediate-Term Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Urothelial Carcinoma.
    J Urol. 2015;194:44.
    PubMed     Text format    


  126. FAN EW, Li CC, Wu WJ, Huang CN, et al
    FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
    J Urol. 2015;194:223-9.
    PubMed     Text format     Abstract available


  127. GIRI V, Jha AK, Tomar V, Banerjee I, et al
    Re: Novel Bladder Preservation Therapy with Osaka Medical College Regimen: H. Azuma, T. Inamoto, K. Takahara, H. Nomi, H. Hirano, N. Ibuki, H. Uehara, K. Komura, K. Minami, T. Uchimoto, K. Saito, T. Takai, N. Tanda, K. Yamamoto, Y. Narumi and S. Kiyam
    J Urol. 2015;194:263.
    PubMed     Text format    


    June 2015
  128. HEMDAN T, Malmstrom PU, Jahnson S, Segersten U, et al
    Emmprin expression predict response and survival following cisplatin-containing chemotherapy - A validation study in bladder cancer patients from two randomized studies of cystectomy with and without neoadjuvant chemotherapy.
    J Urol. 2015 Jun 25. pii: S0022-5347(15)04296-2. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  129. LUCHEY AM, Lin HY, Yue B, Agarwal G, et al
    Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer.
    J Urol. 2015 Jun 5. pii: S0022-5347(15)04113-0. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  130. HAYASHI T, Seiler R, Oo HZ, Jager W, et al
    Targeting HER2 with T-DM1, an Antibody-cytotoxic Drug Conjugate, is effective in HER2-overexpressing bladder cancer.
    J Urol. 2015 Jun 2. pii: S0022-5347(15)04105-1. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  131. CHANG SS
    Re: Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study with Molecular Correlates of Response and Toxicit
    J Urol. 2015;193:1932.
    PubMed     Text format    


  132. CHANG SS
    Re: long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    J Urol. 2015;193:1931-2.
    PubMed     Text format    


  133. GANGKAK G, Giri V, Yadav SS
    Re: Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer: S. Daneshmand, H. Ahmadi, A. K. Schuckman, A. P. Mitra, J. Cai, G. Miranda and H. Djaladat J Urol 2014;192:50-56.
    J Urol. 2015 Jun 1. pii: S0022-5347(15)03726-X. doi: 10.1016/j.juro.2015.02.2950
    PubMed     Text format    


  134. BANERJEE I, Giri V, Tomar V
    Re: The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A. Meyer, R. Ghandour, A. Bergman, C. Castaneda, M. Wosnitzer, G. Hruby, M. Benson and J. McKiernan J Urol 2014; 192: 696-70
    J Urol. 2015;193:2152.
    PubMed     Text format    


    May 2015
  135. CHAN KG, Collins JW, Wiklund NP
    Robot-assisted radical cystectomy: extracorporeal vs intracorporeal urinary diversion.
    J Urol. 2015;193:1467-9.
    PubMed     Text format    


  136. FRYE TP, Sadowski DJ, Zahnd WE, Jenkins WD, et al
    Impact of county rurality and urologist density on urological cancer mortality in illinois.
    J Urol. 2015;193:1608-13.
    PubMed     Text format     Abstract available


  137. PSUTKA SP, Boorjian SA, Moynagh MR, Schmit GD, et al
    Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting.
    J Urol. 2015;193:1507-13.
    PubMed     Text format     Abstract available


  138. PARKER WP, Ho PL, Melquist JJ, Scott K, et al
    The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
    J Urol. 2015;193:1494-9.
    PubMed     Text format     Abstract available


  139. SKOLARUS TA, Jacobs BL, Schroeck FR, He C, et al
    Understanding hospital readmission intensity after radical cystectomy.
    J Urol. 2015;193:1500-6.
    PubMed     Text format     Abstract available


  140. DOWNS TM
    Reducing readmissions and mortality after radical cystectomy.
    J Urol. 2015;193:1461-2.
    PubMed     Text format    


  141. ODISHO AY
    Editorial comment.
    J Urol. 2015;193:1613.
    PubMed     Text format    



  142. Reply by author.
    J Urol. 2015;193:1613-4.
    PubMed     Text format    


    March 2015
  143. ATALA A
    Re: Mutations in 3'-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb.
    J Urol. 2015;193:1061.
    PubMed     Text format    


  144. ROUANNE M, Lebret T, Courbebaisse M
    Re: Long-term renal function outcomes after radical cystectomy.
    J Urol. 2015;193:1066-7.
    PubMed     Text format    


  145. WU TF, Li CF, Chien LH, Shen KH, et al
    Galectin-1 dysregulation independently predicts disease specific survival in bladder urothelial carcinoma.
    J Urol. 2015;193:1002-8.
    PubMed     Text format     Abstract available


    February 2015
  146. DOWNS T
    Editorial comment.
    J Urol. 2015;193:450.
    PubMed     Text format    


  147. DREICER R
    Interdisciplinary management of locally advanced and metastatic genitourinary cancers: a team sport.
    J Urol. 2015;193:389-90.
    PubMed     Text format    


  148. LAU CS, Blackwell RH, Quek ML
    Radical cystectomy: open vs robotic approach.
    J Urol. 2015;193:400-2.
    PubMed     Text format    


  149. GLEASON JM, Bowlin PR, Bagli DJ, Lorenzo AJ, et al
    A comprehensive review of pediatric urachal anomalies and predictive analysis for adult urachal adenocarcinoma.
    J Urol. 2015;193:632-6.
    PubMed     Text format     Abstract available


  150. YOUSSEF RF, von Rundstedt FC, Kapur P, Mosbah A, et al
    Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma.
    J Urol. 2015;193:451-6.
    PubMed     Text format     Abstract available


  151. SUN AJ, Djaladat H, Schuckman A, Miranda G, et al
    Venous thromboembolism following radical cystectomy: significant predictors, comparison of different anticoagulants and timing of events.
    J Urol. 2015;193:565-9.
    PubMed     Text format     Abstract available


    October 2014
  152. ZABELL JR, Adejoro O, Konety BR, Weight CJ, et al
    Risk of End-Stage Kidney Disease after Radical Cystectomy According to Urinary Diversion Type.
    J Urol. 2014 Oct 31. pii: S0022-5347(14)04805-8. doi: 10.1016/j.juro.2014.
    PubMed     Text format     Abstract available


    August 2014
  153. AZUMA H, Inamoto T, Takahara K, Nomi H, et al
    Novel Bladder Preservation Therapy, OMC-Regimen: Combined Therapy using Balloon-Occluded Arterial Infusion of Anticancer Agent and Hemodialysis with Concurrent Radiation.
    J Urol. 2014 Aug 25. pii: S0022-5347(14)04349-3. doi: 10.1016/j.juro.2014.
    PubMed     Text format     Abstract available


    July 2014
  154. HERR HW
    The Risk of Urinary Tract Infection after Flexible Cystoscopy in Bladder Tumor Patients who did not receive Prophylactic Antibiotics.
    J Urol. 2014 Jul 18. pii: S0022-5347(14)03963-9. doi: 10.1016/j.juro.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: